Evidence map›Paper›PMID 27573673›Full record

ReviewDer Nervenarzt2016

[Psychopharmacotherapy during pregnancy : Which antipsychotics, tranquilizers and hypnotics are suitable?].

N Bergemann, W E Paulus

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

N BergemannSächsisches Krankenhaus Rodewisch, Zentrum für Psychiatrie, Psychotherapie, Psychosomatik und Neurologie, Bahnhofstraße 1, 08228, Rodewisch, Deutschland. niels.bergemann@skhro.sms.sachsen.de.
W E PaulusInstitut für Reproduktionstoxikologie, Krankenhaus St. Elisabeth, Ravensburg, Deutschland.
Elisabeth-Krankenhaus Essen · DESächsisches Krankenhaus Rodewisch · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhen administering psychotropic drugs during pregnancy not only the potential teratogenic effects on the child must be addressed but also the fetotoxic implications for pregnancy and/or the peripartum phase as well as possible neurocognitive developmental disorders must be considered.

objectiveEvaluation of the risks and benefits of administering psychotropic drugs during pregnancy or for women who wish to become pregnant.

methodsThe literature has been reviewed with the purpose of providing information on psychotropic drugs which can safely be administered during pregnancy. The review considers antipsychotics as well as tranquilizers and hypnotics.

resultsData are available for a multitude of psychotropic drugs that allow a safe estimation on their suitability for use during pregnancy.

conclusionWhen treating mental illnesses during pregnancy the option of administering drugs must not principally be ruled out. What is required is an individual assessment of benefits and risks. The risk of an untreated mental illness versus the benefit of a suitable treatment, which may include the use of medication and the potential harm to the infant must be evaluated. If certain rules are observed and a suitable drug is selected the risk to the newborn child and/or mother during pregnancy can be minimized. During pregnancy, therapeutic drug monitoring is indicated and increases the safety for use of drugs and preventing harm to both mother and infant.

Indexed as

Abnormalities, Drug-InducedAntipsychotic AgentsDrug Administration ScheduleDrug MonitoringDrug Therapy, CombinationEvidence-Based MedicineFemaleHumansHypnotics and SedativesMaternal-Fetal ExchangeMental DisordersPregnancyPregnancy ComplicationsPrenatal Exposure Delayed EffectsPsychopharmacologyTranquilizing AgentsAntipsychotic AgentsHypnotics and SedativesTranquilizing AgentsDrug-induced abnormalitiesNeurocognitive disordersReviewRisk-benefit assessmentTransplacental exposure

Identifiers

PMID27573673
OpenAlexW2513830997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.